Loading...
Multiple Trial And Dilution Risks Will Shape Future Immunology Upside Potential
AN
AnalystLowTarget
Not Invested
Community Contributor
Published
02 Apr 26
Views
2
02 Apr
US$11.90
AnalystLowTarget's Fair Value
US$27.00
55.9% undervalued intrinsic discount1Y
179.3%7D
6.7%1Y
179.3%7D
6.7%You can edit this narrative until Apr 3 11:10 PM. Then, changes will post as Updates.
Author's Valuation
US$2755.9% undervalued intrinsic discount
AnalystLowTarget Fair Value